Nabriva Therapeutics plc NBRVF

Company Overview

Nabriva Therapeutics plc (OTC: NBRVF) was a biopharmaceutical company focused on the development and commercialization of anti-infective therapies, particularly antibiotics targeting drug-resistant bacterial infections. The company operated within the biotechnology and pharmaceutical industries, with a primary emphasis on treating serious community-acquired respiratory and bacterial infections. Its principal commercial product was XENLETA (lefamulin), a pleuromutilin antibiotic approved in the United States for the treatment of community-acquired bacterial pneumonia (CABP). The company also advanced additional anti-infective candidates through development partnerships and licensing arrangements.

Nabriva evolved from Austrian biotechnology operations originally organized as Nabriva Therapeutics AG before redomiciling to Ireland and becoming Nabriva Therapeutics plc. The company positioned itself around differentiated anti-infective compounds designed to address antimicrobial resistance and unmet medical needs in hospital and community care settings. Its strategic differentiation was tied to the development of pleuromutilin-class antibiotics for both intravenous and oral administration. Public filings and market disclosures indicate that the company faced substantial financial and operational pressures following commercialization efforts for XENLETA, and later corporate activity reduced its independent operating profile. Data regarding its current standalone operating status is inconclusive based on available public sources.